ArticleBMC cancer2025
Peripheral lymphocyte count as a prognostic marker in cervical cancer patients treated with immune checkpoint inhibitors: a retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Peripheral blood lymphocyte and eosinophil dynamics with chemotherapy and pembrolizumab in cervical cancer.International journal of clinical oncology · 2026Article
- Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance.Frontiers in immunology · 2026Review
- The ALP score: a novel composite index for prognostic risk stratification to chemo-immunotherapy in advanced non-small cell lung cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab, an immune checkpoint inhibitor (ICI), has revolutionized the treatment of recurrent cervical cancer; however, its benefits are limited. This study investigated whether peripheral lymphocyte count (PLC) is a prognostic factor for ICI in patients with advanced or recurrent cervical cancer.
methodsThis retrospective study included 47 patients diagnosed with advanced or recurrent cervical cancer, who were treated with pembrolizumab at our hospital between September 2022 and December 2024. The primary outcome was progression-free survival (PFS). The PLC was measured using a blood test conducted immediately before the first administration of pembrolizumab. The optimal PLC cut-off value was determined by using the first quartile point of the PLC distribution. Based on this cut-off value, the patients were allocated into two groups: a normal PLC group (PLChigh) and low PLC group (PLClow). The impact of PLC on PFS was assessed using a Cox proportional hazards regression model using inverse probability of treatment weighting method based on the propensity score, as well as the log-rank test.
resultsThe median age of the participants was 55 years (interquartile range, 34–84 years). The most common histological type was squamous cell carcinoma (60% of cases). The cut-off value for PLC was set at 710/µL based on the first quartile point. Twelve patients had PLClow (26%) and 35 had PLChigh (74%). Low PLC was significantly associated with shorter PFS (hazard ratio [HR], 2.91, 95% confidence interval [CI], 1.23–6.91, p = 0.013). In the sensitivity analysis, low PLC was also significantly associated with shorter PFS (HR, 4.10; 95% CI, 1.81–9.29, p < 0.001).
conclusionsPLC may have potential as a prognostic marker for immunochemotherapy in patients with advanced or recurrent cervical cancer. Pre-treatment assessment of PLC could be helpful in identifying patients at risk of poor outcomes and in supporting clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.